Two Sigma Advisers’s INmune Bio INMB Stock Holding History

Two Sigma Advisers’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-12,700	Closed	-$59.3K	–	2480
2024 Q4	$59.3K	Buy	+12,700	New	+$66.2K	﹤0.01%	2271

Other funds holding INMB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Praetorian PR Rincon, Puerto Rico $275M AUM 84.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Advisers's INMB Position: Q1 2025 in Review

Two Sigma Advisers sold out of INmune Bio (INMB) in Q1 2025, closing a stake of 12,700 shares — an estimated $59.3K sold.

Two Sigma Advisers first reported a position in INMB in Q4 2024 and held it in 1 quarter. The position peaked at $59.3K in Q4 2024. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2025.

Two Sigma Advisers reported no remaining INmune Bio position as of Q1 2025 after selling out during the quarter.
Two Sigma Advisers sold 12,700 INmune Bio shares in Q1 2025, an estimated $59.3K.
Two Sigma Advisers first reported a position in INmune Bio in Q4 2024 and held it in 1 quarter.
Two Sigma Advisers's INmune Bio position peaked at $59.3K in Q4 2024.
82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2025.

Based on Two Sigma Advisers's 13F filing for Q1 2025, filed 15 May 2025.